Skip to main content
Top
Published in: BMC Geriatrics 1/2022

Open Access 01-12-2022 | Dementia | Research article

Population attributable fractions for risk factors and disability burden of dementia in Jiangxi Province, China: a cross-sectional study

Authors: Yuhang Wu, Huilie Zheng, Fenfei Xu, Jin Guo, Zhitao Liu, Shengwei Wang, Xiaoyun Chen, Yu Cao, Wei Zou, Songbo Hu

Published in: BMC Geriatrics | Issue 1/2022

Login to get access

Abstract

Background

In view of the fact that there is no effective treatment for dementia, the number of years that dementia patients have to live with dementia will gradually increase for the rest of their lives, and the disability loss caused by dementia will increase. It is urgent to study the influence of risk factors on dementia by making use of the potential of prevention. The purpose of this study is to quantify the burden of dementia disability attributable to risk factors by assessing the population attributable fractions (PAFs) in Jiangxi Province, which is one of the regions of moderate aging process of China.

Methods

The prevalence data of nine risk factors were obtained through the Sixth National Health Service Survey in 2018, which covered 2713 older people. Levin’s formula was used to calculate the PAF for each risk factor for dementia. We adjusted the PAF for communality between risk factors, and used these values to calculate overall weighted PAFs and the years lived with disability (YLDs), which were attributable to nine risk factors.

Results

The number of dementia cases and their proportions that can theoretically be prevented by nine identified risk factors were 111636 (99595-120877) and 66.8% (59.6-72.3), respectively. The total YLDs of dementia were estimated to be 61136 (46463-78369) (males: 36434 [24100-49330], females: 23956 [14716-34589]). Physical inactivity (11639 [8845-14920]), low social contact (9324 [7086-11952]), and hearing loss (5668 [4307-7265] were the top three contributors to dementia.

Conclusions

The moderate aging areas represented by Jiangxi Province have great potential in the prevention of dementia. Targeted interventions and management of risk factors can effectively reduce the disability burden of dementia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nichols E, Szoeke C, Vollset SE, Abbasi N, Murray CJL. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.CrossRef Nichols E, Szoeke C, Vollset SE, Abbasi N, Murray CJL. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.CrossRef
2.
go back to reference Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5(12):e661–e71.PubMedCrossRef Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5(12):e661–e71.PubMedCrossRef
3.
go back to reference Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19(1):81–92.PubMedCrossRef Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19(1):81–92.PubMedCrossRef
4.
go back to reference Li R, Qi J, Yang Y, Wu Y, Yin P, Zhou M, et al. Disease burden and attributable risk factors of alzheimer’s disease and dementia in China from 1990 to 2019. J Prev Alzheimers Dis. 2022;9(2):306–14.PubMed Li R, Qi J, Yang Y, Wu Y, Yin P, Zhou M, et al. Disease burden and attributable risk factors of alzheimer’s disease and dementia in China from 1990 to 2019. J Prev Alzheimers Dis. 2022;9(2):306–14.PubMed
5.
go back to reference Charlson FJ, Baxter AJ, Cheng HG, Shidhaye R, Whiteford HA. The burden of mental, neurological, and substance use disorders in China and India: a systematic analysis of community representative epidemiological studies. Lancet. 2016;388(10042):376–89. https://doi.org/10.1016/S0140-6736(16)30590-6. Charlson FJ, Baxter AJ, Cheng HG, Shidhaye R, Whiteford HA. The burden of mental, neurological, and substance use disorders in China and India: a systematic analysis of community representative epidemiological studies. Lancet. 2016;388(10042):376–89. https://​doi.​org/​10.​1016/​S0140-6736(16)30590-6.
6.
go back to reference Li N, Zhang L, Du W, Pang L, Guo C, Chen G, et al. Prevalence of dementia-associated disability among chinese older adults: results from a national sample survey. Am J Geriatr Psychiatry. 2015;23(3):320–5.PubMedCrossRef Li N, Zhang L, Du W, Pang L, Guo C, Chen G, et al. Prevalence of dementia-associated disability among chinese older adults: results from a national sample survey. Am J Geriatr Psychiatry. 2015;23(3):320–5.PubMedCrossRef
7.
go back to reference Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimer’s Dementia. 2018;14(4):483–91.PubMedCrossRef Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimer’s Dementia. 2018;14(4):483–91.PubMedCrossRef
8.
go back to reference Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.PubMedCrossRef Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.PubMedCrossRef
10.
go back to reference Pickett J, Brayne C. The scale and profile of global dementia research funding. Lancet. 2019;394:1888–9.PubMedCrossRef Pickett J, Brayne C. The scale and profile of global dementia research funding. Lancet. 2019;394:1888–9.PubMedCrossRef
11.
go back to reference Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dementia. 2007;3(3):186–91.PubMedCrossRef Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dementia. 2007;3(3):186–91.PubMedCrossRef
12.
go back to reference Liu Y, Zhang S, Tomata Y, Nurrika D, Sugawara Y, Tsuji I. The impact of risk factors for dementia in China. Age Ageing. 2020;49(5):850–5.PubMedCrossRef Liu Y, Zhang S, Tomata Y, Nurrika D, Sugawara Y, Tsuji I. The impact of risk factors for dementia in China. Age Ageing. 2020;49(5):850–5.PubMedCrossRef
13.
go back to reference Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. Lancet Global Health. 2019;7(5):e596–603.PubMedCrossRef Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. Lancet Global Health. 2019;7(5):e596–603.PubMedCrossRef
16.
go back to reference Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–58.PubMedPubMedCentralCrossRef Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–58.PubMedPubMedCentralCrossRef
17.
go back to reference Wu Y, Zheng H, Liu Z, Wang S, Hu S. Dementia-Free Life Expectancy among People over 60 Years Old by Sex, Urban and Rural Areas in Jiangxi Province, China. Int J Environ Res Public Health. 2020;17(16):5665.PubMedCentralCrossRef Wu Y, Zheng H, Liu Z, Wang S, Hu S. Dementia-Free Life Expectancy among People over 60 Years Old by Sex, Urban and Rural Areas in Jiangxi Province, China. Int J Environ Res Public Health. 2020;17(16):5665.PubMedCentralCrossRef
18.
go back to reference Fan LY, Sun Y, Lee HJ, Yang SC, Chen TF, Lin KN, et al. Marital status, lifestyle and dementia: a nationwide survey in Taiwan. Plos One. 2015;10(9):e0139154.PubMedPubMedCentralCrossRef Fan LY, Sun Y, Lee HJ, Yang SC, Chen TF, Lin KN, et al. Marital status, lifestyle and dementia: a nationwide survey in Taiwan. Plos One. 2015;10(9):e0139154.PubMedPubMedCentralCrossRef
19.
go back to reference Deng J, Cao C, Jiang Y, Peng B, Wang T, Yan K, et al. Prevalence and effect factors of dementia among the community elderly in Chongqing, China. Psychogeriatrics. 2018;18(5):412–20.PubMedCrossRef Deng J, Cao C, Jiang Y, Peng B, Wang T, Yan K, et al. Prevalence and effect factors of dementia among the community elderly in Chongqing, China. Psychogeriatrics. 2018;18(5):412–20.PubMedCrossRef
20.
go back to reference Murray C, Aravkin A, Zheng P, Cristiana A, Abbas K, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories 1990-2019: a systematic analysis for the GBD Study 2019. J Lancet. 2020;396:1223–49.CrossRef Murray C, Aravkin A, Zheng P, Cristiana A, Abbas K, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories 1990-2019: a systematic analysis for the GBD Study 2019. J Lancet. 2020;396:1223–49.CrossRef
21.
go back to reference Gauthier S, Rockwood K, Gélinas I, Sykes L, Teunisse S, Orgogozo JM, et al. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S143–7.PubMed Gauthier S, Rockwood K, Gélinas I, Sykes L, Teunisse S, Orgogozo JM, et al. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S143–7.PubMed
22.
go back to reference Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24(4):637–9.PubMed Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24(4):637–9.PubMed
23.
go back to reference Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.PubMedPubMedCentralCrossRef Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.PubMedPubMedCentralCrossRef
24.
go back to reference Jonas C, Schiffczyk C, Lahmeyer C, Mueller F, Riepe MW. Staging dementia using proxy-reported activities of daily living. Dement Geriatr Cogn Disord. 2011;32(2):111–7.PubMedCrossRef Jonas C, Schiffczyk C, Lahmeyer C, Mueller F, Riepe MW. Staging dementia using proxy-reported activities of daily living. Dement Geriatr Cogn Disord. 2011;32(2):111–7.PubMedCrossRef
25.
go back to reference Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8(3):448–60.PubMedCrossRef Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8(3):448–60.PubMedCrossRef
26.
go back to reference De la Rosa A, Olaso-Gonzalez G, Arc-Chagnaud C, Millan F, Salvador-Pascual A, García-Lucerga C, et al. Physical exercise in the prevention and treatment of Alzheimer’s disease. J Sport Health Sci. 2020;9(5):394–404.PubMedPubMedCentralCrossRef De la Rosa A, Olaso-Gonzalez G, Arc-Chagnaud C, Millan F, Salvador-Pascual A, García-Lucerga C, et al. Physical exercise in the prevention and treatment of Alzheimer’s disease. J Sport Health Sci. 2020;9(5):394–404.PubMedPubMedCentralCrossRef
27.
go back to reference Adams R, Blieszner R. Aging Well With Friends and Family. Amer Behav Sci. 1995;39:209–24.CrossRef Adams R, Blieszner R. Aging Well With Friends and Family. Amer Behav Sci. 1995;39:209–24.CrossRef
29.
go back to reference Xiang X, Lai PHL, Bao L, Sun Y, Chen J, Dunkle RE, et al. Dual trajectories of social isolation and dementia in older adults: a population-based longitudinal study. J Aging Health. 2021;33(1-2):63–74.PubMedCrossRef Xiang X, Lai PHL, Bao L, Sun Y, Chen J, Dunkle RE, et al. Dual trajectories of social isolation and dementia in older adults: a population-based longitudinal study. J Aging Health. 2021;33(1-2):63–74.PubMedCrossRef
32.
go back to reference Takeda S, Rakugi H, Morishita R. Roles of vascular risk factors in the pathogenesis of dementia. Hypertens Res. 2020;43(3):162–7.PubMedCrossRef Takeda S, Rakugi H, Morishita R. Roles of vascular risk factors in the pathogenesis of dementia. Hypertens Res. 2020;43(3):162–7.PubMedCrossRef
33.
go back to reference Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19(3):24.PubMedPubMedCentralCrossRef Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19(3):24.PubMedPubMedCentralCrossRef
34.
go back to reference Ma S, Yang L, Zhao M, Magnussen CG, Xi B. Trends in hypertension prevalence, awareness, treatment and control rates among Chinese adults, 1991-2015. J Hypertens. 2021;39(4):740–8.PubMedCrossRef Ma S, Yang L, Zhao M, Magnussen CG, Xi B. Trends in hypertension prevalence, awareness, treatment and control rates among Chinese adults, 1991-2015. J Hypertens. 2021;39(4):740–8.PubMedCrossRef
35.
go back to reference Deborah E, Barnes TJH, Mehta KM, Carlson MC, Kuller LH, Tager IB. Secondhand smoke, vascular disease, and dementia incidence: findings from the cardiovascular health cognition study. Am J Epidemiol. 2010;171(3):292.CrossRef Deborah E, Barnes TJH, Mehta KM, Carlson MC, Kuller LH, Tager IB. Secondhand smoke, vascular disease, and dementia incidence: findings from the cardiovascular health cognition study. Am J Epidemiol. 2010;171(3):292.CrossRef
37.
go back to reference Swan GE, Lessov-Schlaggar CN. The Effects of Tobacco Smoke and Nicotine on Cognition and the Brain. Neuropsychol Rev. 2007;17(3):259–73.PubMedCrossRef Swan GE, Lessov-Schlaggar CN. The Effects of Tobacco Smoke and Nicotine on Cognition and the Brain. Neuropsychol Rev. 2007;17(3):259–73.PubMedCrossRef
38.
go back to reference Håkansson K, Rovio S, Helkala EL, Vilska AR, Winblad B, Soininen H, et al. Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ. 2009;339:b2462.PubMedPubMedCentralCrossRef Håkansson K, Rovio S, Helkala EL, Vilska AR, Winblad B, Soininen H, et al. Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ. 2009;339:b2462.PubMedPubMedCentralCrossRef
39.
go back to reference Penninkilampi R, Casey AN, Singh MF, Brodaty H. The association between social engagement, loneliness, and risk of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2018;66(4):1619–33.PubMedCrossRef Penninkilampi R, Casey AN, Singh MF, Brodaty H. The association between social engagement, loneliness, and risk of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2018;66(4):1619–33.PubMedCrossRef
41.
go back to reference Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.PubMedCrossRef Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.PubMedCrossRef
42.
go back to reference Telenius EW, Tangen GG, Eriksen S, Rokstad AMM. Fun and a meaningful routine: the experience of physical activity in people with dementia. BMC Geriatr. 2022;22(1):500.PubMedPubMedCentralCrossRef Telenius EW, Tangen GG, Eriksen S, Rokstad AMM. Fun and a meaningful routine: the experience of physical activity in people with dementia. BMC Geriatr. 2022;22(1):500.PubMedPubMedCentralCrossRef
43.
go back to reference Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202.PubMedCrossRef Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202.PubMedCrossRef
Metadata
Title
Population attributable fractions for risk factors and disability burden of dementia in Jiangxi Province, China: a cross-sectional study
Authors
Yuhang Wu
Huilie Zheng
Fenfei Xu
Jin Guo
Zhitao Liu
Shengwei Wang
Xiaoyun Chen
Yu Cao
Wei Zou
Songbo Hu
Publication date
01-12-2022
Publisher
BioMed Central
Keywords
Dementia
Dementia
Published in
BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-022-03507-4

Other articles of this Issue 1/2022

BMC Geriatrics 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine